CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ENSA (ImmuneEditome ID:2029)

1. Gene summary of enriched editing regions for ENSA

check button Gene summary
Gene informationGene symbol

ENSA

Gene ID

2029

GeneSynonymsARPP-19e
GeneCytomap

1q21.3

GeneTypeprotein-coding
GeneDescriptionalpha-endosulfine
GeneModificationdate20230329
UniprotIDO43768;A6NMQ3;A0A1W2PRU0;Q5T5H1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:150600832-150603955:-ENST00000369016.7ENSG00000143420.16ENSAexonicAluSx3,FLAM_C,(TATATA)n,(T)n,L1ME3G,AluJb,AluSx4,FLAM_A,L3,AluSq2,L1HS,AluSx1chr1:150600832-150603955:-.alignment
chr1:150620647-150621595:-ENST00000369014.8ENSG00000143420.16ENSAUTR3MIR,AluSz,AluJb,AluJrchr1:150620647-150621595:-.alignment


Top

2. Tumor-specific enriched editing regions for ENSA


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:150600832-150603955:-BRCAEER4.7599e-02image
chr1:150620647-150621595:-LUSCEER1.6980e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr1:150620647-150621595:-STADPathEER4.7019e-031.3269e-030.2196image
ENSG00000143420.16,ENSASTADPathEAG1.0373e-034.0626e-040.2110image
chr1:150600832-150603955:-STADPathEER2.1274e-027.6546e-030.2192image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ENSA


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ENSA


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000143420.16,ENSA
ESCAEAGIRENSG00000143774.12chr1228145509:228145649:228146025:228146066-0.34182.7534e-021.4305e-07-0.4074imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000143420.16,ENSA
ESCAEAGIRENSG00000006453.9chr798307981:98308382:98310444:98310592-0.36116.4664e-037.7963e-07-0.4020imageNACIN1;ADAR;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAMast_cells_activatedGSVA_HALLMARK_ADIPOGENESIS
ENSG00000143420.16,ENSA
ESCAEAGIRENSG00000197226.8chr5179871461:179871530:179871719:179871805-0.34921.1408e-025.4005e-07-0.4046imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000143420.16,ENSA
ESCAEAGIRENSG00000197114.7chr2063733218:63733739:63734644:63734824-0.36887.3417e-032.6265e-08-0.4338imageNACIN1;ADAR;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000143420.16,ENSA
GBMEAGIRENSG00000125459.10chr1155746795:155747680:155747761:155747845-0.37501.4381e-024.2199e-06-0.4013imageNACIN1;ADAR;AIFM1;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX42;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA2B1;HNRNPK;IGF2BP2;IGF2BP3;LIN28;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;RBM22;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAGNANeutrophilsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000143420.16,ENSA
OVEAGIRENSG00000172613.3chr1167391982:67392782:67393537:67393610-0.31699.9982e-065.9708e-12-0.4422imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZNF184RAD9AGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000143420.16,ENSA
OVEAGIRENSG00000131981.11chr1455137368:55137694:55138044:55138368-0.30301.3289e-052.9947e-11-0.4427imageNACIN1;ADAR;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LIN28;MOV10;MSI1;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM47;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TIAL1;U2AF1;U2AF2;UPF1LGALS3Macrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000143420.16,ENSA
THYMEAGA5ENSG00000168653.6chr139028722:39028750:39026317:39026398:39026317:390264020.37743.1165e-024.0891e-060.4550imageNACIN1;ADAR;AIFM1;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZC3H7B;ZNF184NAEosinophils
ENSG00000143420.16,ENSA
THYMEAGA3ENSG00000091164.8chr1856626161:56626266:56624287:56624400:56624287:566244610.15881.4292e-021.4878e-060.5356imageNACIN1;ADAR;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NA
ENSG00000143420.16,ENSA
THYMEAGA5ENSG00000182511.7chr1590886960:90887015:90884712:90885258:90884712:90885585-0.30404.6569e-024.7675e-04-0.4094imageNADAR;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MSI2;NONO;NOP56;NOP58;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1;XRN2NAMacrophages_M1GSVA_HALLMARK_TGF_BETA_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for ENSA


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:150620647-150621595:-BLCAEERT_cells_CD4_memory_resting4.1793e-020.1681image
ENSG00000143420.16,ENSABLCAEAGT_cells_CD4_memory_resting2.6828e-020.1517image
chr1:150600832-150603955:-BRCAEERNK_cells_activated1.4125e-02-0.1150image
chr1:150620647-150621595:-BRCAEERT_cells_CD4_memory_resting4.7231e-02-0.0756image
ENSG00000143420.16,ENSABRCAEAGNK_cells_activated2.5493e-02-0.0756image
chr1:150600832-150603955:-CESCEERPlasma_cells4.8534e-02-0.2457image
chr1:150620647-150621595:-CESCEERMacrophages_M18.3047e-03-0.2036image
ENSG00000143420.16,ENSACHOLEAGT_cells_CD4_memory_resting3.8234e-020.4086image
chr1:150600832-150603955:-COADEERNeutrophils2.5616e-030.5764image
ENSG00000143420.16,ENSACOADEAGDendritic_cells_activated6.2499e-030.3676image
chr1:150620647-150621595:-ESCAEERT_cells_gamma_delta8.5758e-070.4019image
ENSG00000143420.16,ENSAESCAEAGT_cells_gamma_delta3.5414e-050.3247image
chr1:150620647-150621595:-GBMEERB_cells_memory4.3364e-030.3930image
ENSG00000143420.16,ENSAGBMEAGB_cells_memory3.2475e-050.3640image
chr1:150600832-150603955:-HNSCEERMonocytes7.3622e-030.5130image
chr1:150620647-150621595:-HNSCEERT_cells_CD4_memory_activated2.8295e-020.1924image
ENSG00000143420.16,ENSAHNSCEAGT_cells_CD4_memory_activated9.4121e-030.1986image
chr1:150600832-150603955:-KIRCEERMonocytes1.3536e-020.2822image
chr1:150620647-150621595:-KIRCEERDendritic_cells_resting3.5027e-020.2177image
chr1:150600832-150603955:-KIRPEERB_cells_naive4.0345e-020.2749image
chr1:150620647-150621595:-KIRPEEREosinophils3.7350e-030.4979image
chr1:150620647-150621595:-LAMLEERDendritic_cells_resting1.2112e-030.2981image
chr1:150600832-150603955:-LGGEERB_cells_memory4.0470e-020.1617image
ENSG00000143420.16,ENSALGGEAGMacrophages_M02.5979e-030.1395image
ENSG00000143420.16,ENSALIHCEAGMonocytes4.3078e-030.2610image
chr1:150600832-150603955:-LUADEERNK_cells_resting1.2030e-020.2110image
chr1:150620647-150621595:-LUADEERNK_cells_activated1.4380e-020.1827image
ENSG00000143420.16,ENSALUADEAGT_cells_CD4_naive7.8520e-030.1636image
chr1:150600832-150603955:-LUSCEERMast_cells_resting9.3401e-030.2756image
chr1:150620647-150621595:-LUSCEERT_cells_regulatory_(Tregs)2.4568e-020.1788image
ENSG00000143420.16,ENSALUSCEAGMast_cells_resting2.1795e-040.2355image
chr1:150600832-150603955:-OVEERNK_cells_activated3.6423e-030.1906image
chr1:150620647-150621595:-OVEERT_cells_regulatory_(Tregs)3.8063e-030.2389image
ENSG00000143420.16,ENSAOVEAGT_cells_regulatory_(Tregs)3.5266e-030.1793image
chr1:150600832-150603955:-PAADEERMonocytes1.9381e-020.4050image
ENSG00000143420.16,ENSAPAADEAGMonocytes1.7298e-020.3228image
chr1:150600832-150603955:-PCPGEERT_cells_gamma_delta5.4414e-080.7318image
chr1:150600832-150603955:-PRADEEREosinophils4.0767e-030.3656image
ENSG00000143420.16,ENSAPRADEAGB_cells_memory8.2718e-03-0.1936image
ENSG00000143420.16,ENSASARCEAGT_cells_follicular_helper3.8958e-020.1806image
ENSG00000143420.16,ENSASKCMEAGT_cells_CD4_naive2.6619e-030.2452image
ENSG00000143420.16,ENSASTADEAGEosinophils1.4696e-02-0.1432image
ENSG00000143420.16,ENSATGCTEAGMast_cells_resting2.9259e-02-0.2352image
chr1:150600832-150603955:-THCAEERNK_cells_activated2.0188e-02-0.2393image
chr1:150620647-150621595:-THCAEERMacrophages_M02.9182e-03-0.2079image
ENSG00000143420.16,ENSATHCAEAGDendritic_cells_resting7.5610e-030.1346image
ENSG00000143420.16,ENSAUCECEAGMonocytes2.7261e-020.2409image
ENSG00000143420.16,ENSAUCSEAGMast_cells_resting3.8344e-020.3622image


Top

6. Enriched editing regions and immune gene sets for ENSA


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:150600832-150603955:-BLCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0618e-020.2545image
ENSG00000143420.16,ENSABLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.4967e-040.2569image
chr1:150620647-150621595:-BRCAGSVA_HALLMARK_MYOGENESISEER1.0838e-050.1666image
chr1:150600832-150603955:-BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.3483e-060.2243image
ENSG00000143420.16,ENSABRCAGSVA_HALLMARK_GLYCOLYSISEAG5.5163e-090.1958image
ENSG00000143420.16,ENSACESCGSVA_HALLMARK_HEME_METABOLISMEAG4.1181e-030.2010image
chr1:150600832-150603955:-CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0613e-020.3149image
chr1:150620647-150621595:-CESCGSVA_HALLMARK_MYC_TARGETS_V2EER8.2533e-03-0.2038image
ENSG00000143420.16,ENSACHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.3735e-020.4421image
chr1:150600832-150603955:-COADGSVA_HALLMARK_NOTCH_SIGNALINGEER1.1480e-02-0.4970image
ENSG00000143420.16,ENSAESCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG7.3452e-070.3842image
chr1:150600832-150603955:-ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER7.3102e-030.2616image
chr1:150620647-150621595:-ESCAGSVA_HALLMARK_MYC_TARGETS_V1EER1.9181e-030.2600image
ENSG00000143420.16,ENSAGBMGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.2812e-050.3705image
chr1:150600832-150603955:-GBMGSVA_HALLMARK_PROTEIN_SECRETIONEER5.0798e-030.3048image
chr1:150620647-150621595:-GBMGSVA_HALLMARK_E2F_TARGETSEER2.5260e-030.4140image
chr1:150600832-150603955:-HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2324e-020.4836image
chr1:150620647-150621595:-HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER7.6469e-030.2330image
ENSG00000143420.16,ENSAHNSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.2519e-030.2455image
ENSG00000143420.16,ENSAKIRCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.4759e-030.2359image
chr1:150600832-150603955:-KIRCGSVA_HALLMARK_MTORC1_SIGNALINGEER8.2775e-040.3756image
chr1:150600832-150603955:-KIRPGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.0037e-020.3101image
ENSG00000143420.16,ENSAKIRPGSVA_HALLMARK_HEME_METABOLISMEAG1.0365e-040.3858image
ENSG00000143420.16,ENSALAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.9487e-020.1629image
chr1:150600832-150603955:-LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER9.2737e-030.2928image
chr1:150620647-150621595:-LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.5775e-03-0.2731image
ENSG00000143420.16,ENSALGGGSVA_HALLMARK_ANGIOGENESISEAG2.5033e-070.2367image
chr1:150600832-150603955:-LGGGSVA_HALLMARK_COAGULATIONEER4.6144e-03-0.2222image
chr1:150600832-150603955:-LIHCGSVA_HALLMARK_MTORC1_SIGNALINGEER3.3793e-020.3823image
ENSG00000143420.16,ENSALIHCGSVA_HALLMARK_PEROXISOMEEAG4.5861e-030.2592image
chr1:150620647-150621595:-LUSCGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.7256e-020.1659image
ENSG00000143420.16,ENSALUSCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.7967e-060.2847image
chr1:150600832-150603955:-LUSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.7405e-040.3898image
chr1:150600832-150603955:-OVGSVA_HALLMARK_HEME_METABOLISMEER1.3424e-030.2098image
ENSG00000143420.16,ENSAOVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.6955e-080.3345image
chr1:150620647-150621595:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.2468e-03-0.2361image
ENSG00000143420.16,ENSAPAADGSVA_HALLMARK_MYC_TARGETS_V1EAG3.2527e-02-0.2914image
chr1:150600832-150603955:-PAADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.4452e-020.3521image
chr1:150620647-150621595:-PRADGSVA_HALLMARK_NOTCH_SIGNALINGEER2.0534e-020.2466image
chr1:150600832-150603955:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER6.5828e-050.4918image
ENSG00000143420.16,ENSAPRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.5046e-070.3609image
ENSG00000143420.16,ENSASARCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG7.7655e-030.2316image
chr1:150600832-150603955:-SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER8.0619e-040.5086image
chr1:150620647-150621595:-SARCGSVA_HALLMARK_DNA_REPAIREER9.8545e-03-0.3421image
ENSG00000143420.16,ENSASKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.9657e-040.2756image
chr1:150600832-150603955:-STADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.6095e-040.2912image
chr1:150620647-150621595:-STADGSVA_HALLMARK_MYC_TARGETS_V2EER2.1592e-030.2067image
ENSG00000143420.16,ENSASTADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.9791e-110.3806image
chr1:150620647-150621595:-THCAGSVA_HALLMARK_ANGIOGENESISEER8.4328e-03-0.1844image
chr1:150600832-150603955:-THCAGSVA_HALLMARK_HEME_METABOLISMEER2.9415e-030.3035image
ENSG00000143420.16,ENSATHCAGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.7460e-020.1198image
ENSG00000143420.16,ENSAUCECGSVA_HALLMARK_APOPTOSISEAG3.5131e-040.3809image
ENSG00000143420.16,ENSAUCSGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.2872e-02-0.3723image


Top

7. Enriched editing regions and drugs for ENSA


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:150620647-150621595:-BLCAJNK.Inhibitor.VIIIEER4.3683e-020.1666image
ENSG00000143420.16,ENSABLCAJNK.Inhibitor.VIIIEAG3.9135e-030.1969image
chr1:150600832-150603955:-BLCAEmbelinEER7.3818e-03-0.2664image
ENSG00000143420.16,ENSABRCAIPA.3EAG7.1296e-060.1515image
chr1:150600832-150603955:-BRCABMS.708163EER1.5622e-05-0.2010image
chr1:150620647-150621595:-BRCAATRAEER8.4770e-070.1864image
ENSG00000143420.16,ENSACESCGW843682XEAG1.2228e-020.1760image
chr1:150600832-150603955:-CESCFTI.277EER1.8554e-03-0.3789image
chr1:150620647-150621595:-CESCGW843682XEER1.3471e-040.2912image
ENSG00000143420.16,ENSACHOLElesclomolEAG3.7358e-020.4103image
chr1:150620647-150621595:-COADCGP.60474EER2.2148e-02-0.4233image
chr1:150600832-150603955:-COADCyclopamineEER1.4374e-030.6133image
chr1:150600832-150603955:-ESCABleomycinEER2.6643e-02-0.2174image
chr1:150620647-150621595:-ESCAAICAREER7.4196e-030.2254image
ENSG00000143420.16,ENSAESCAIPA.3EAG2.7323e-020.1773image
ENSG00000143420.16,ENSAGBMBIRB.0796EAG6.0323e-040.3038image
chr1:150600832-150603955:-GBMGW843682XEER1.1134e-030.3517image
chr1:150620647-150621595:-GBMLFM.A13EER4.0965e-030.3953image
chr1:150600832-150603955:-HNSCBMS.754807EER1.1184e-020.4893image
chr1:150620647-150621595:-HNSCGW843682XEER5.3233e-030.2431image
ENSG00000143420.16,ENSAHNSCBMS.509744EAG2.7371e-030.2284image
ENSG00000143420.16,ENSAKIRCBIRB.0796EAG1.3769e-020.1838image
chr1:150620647-150621595:-KIRCGNF.2EER1.6708e-02-0.2463image
chr1:150600832-150603955:-KIRCJNK.9LEER2.2193e-02-0.2621image
chr1:150600832-150603955:-KIRPGDC.0449EER7.7815e-030.3521image
ENSG00000143420.16,ENSAKIRPFH535EAG1.9591e-02-0.2379image
chr1:150620647-150621595:-KIRPDocetaxelEER6.6903e-030.4696image
chr1:150600832-150603955:-LAMLBryostatin.1EER3.0163e-020.2457image
ENSG00000143420.16,ENSALAMLAZD6482EAG3.1031e-02-0.1786image
chr1:150620647-150621595:-LGGFTI.277EER1.3059e-05-0.3991image
ENSG00000143420.16,ENSALGGEHT.1864EAG1.2647e-110.3076image
chr1:150600832-150603955:-LGGKU.55933EER1.0815e-030.2553image
chr1:150600832-150603955:-LIHCAZD7762EER3.2372e-02-0.3852image
chr1:150620647-150621595:-LUADGW.441756EER2.6995e-02-0.1653image
ENSG00000143420.16,ENSALUADBI.D1870EAG2.2315e-030.1878image
chr1:150600832-150603955:-LUADEmbelinEER6.7787e-03-0.2270image
chr1:150620647-150621595:-LUSCJNK.9LEER1.2024e-03-0.2554image
ENSG00000143420.16,ENSALUSCGNF.2EAG2.2467e-03-0.1955image
chr1:150600832-150603955:-LUSCABT.263EER4.8459e-030.2977image
chr1:150600832-150603955:-OVBI.D1870EER4.7730e-020.1304image
ENSG00000143420.16,ENSAOVBAY.61.3606EAG2.9657e-050.2545image
chr1:150620647-150621595:-OVEmbelinEER4.2265e-060.3715image
ENSG00000143420.16,ENSAPAADLapatinibEAG1.2710e-02-0.3370image
ENSG00000143420.16,ENSAPCPGAKT.inhibitor.VIIIEAG1.6180e-03-0.2759image
ENSG00000143420.16,ENSAPRADAZD.2281EAG2.8361e-040.2653image
chr1:150600832-150603955:-PRADA.770041EER3.9629e-030.3696image
ENSG00000143420.16,ENSASARCElesclomolEAG2.9305e-020.1905image
chr1:150600832-150603955:-SARCDMOGEER1.9731e-02-0.3673image
chr1:150620647-150621595:-SARCGemcitabineEER8.1393e-030.3502image
ENSG00000143420.16,ENSASKCMCGP.082996EAG1.2051e-03-0.2636image
chr1:150620647-150621595:-STADGW843682XEER1.6915e-02-0.1616image
ENSG00000143420.16,ENSASTADAZ628EAG4.4849e-06-0.2657image
chr1:150620647-150621595:-THCABIRB.0796EER9.9781e-03-0.1805image
chr1:150600832-150603955:-THCABMS.536924EER7.3227e-040.3477image
ENSG00000143420.16,ENSATHCABMS.708163EAG2.1923e-03-0.1541image
ENSG00000143420.16,ENSATHYMBMS.754807EAG3.6336e-020.2162image
chr1:150620647-150621595:-UCECAxitinibEER2.3971e-02-0.3521image
ENSG00000143420.16,ENSAUCSAZD7762EAG9.0305e-030.4474image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType